Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Bayer-Evotec partnership targets endometriosis
November 2012
SHARING OPTIONS:

HAMBURG, Germany—A five-year collaboration was announced at the beginning of last month between Evotec AG and Bayer Pharma AG. The multitarget collaboration aims to develop three clinical candidates for the treatment of endometriosis, and both partners will contribute drug targets and technology infrastructures to the effort. The responsibility for early research and preclinical characterization of potential clinical candidates will also be shared, and Bayer will be responsible for subsequent clinical development and commercialization. Evotec will receive an upfront payment of $15.7 million, as well as up to $757.9 million in preclinical, clinical and sales milestones. Evotec will also be eligible for royalties of up to low double-digit percentages of net sales, based on successful development and which party provides the compound.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.